News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript [Seeking Alpha]

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

On National Viagra Day, Women Finally Claim Their Turn:

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

3/26/2026

04:01 pm

dare

2.6%

MISS

11/13/2025

04:01 pm

dare

-3.4%

BEAT

8/14/2025

04:01 pm

dare

7.3%

BEAT

5/13/2025

04:01 pm

dare

0.0%

BEAT

Form 8-K Dare Bioscience, Inc. For: Apr 10

Form QUALIF Dare Bioscience, Inc.

Form 253G2 Dare Bioscience, Inc.

Form 1-A POS Dare Bioscience, Inc.

Form 10-K Dare Bioscience, Inc. For: Dec 31

Top News Decliners

11/21 Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform -16.7%

4/28 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $7.50 price target on the stock. -16.0%

1/30 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule -14.4%

11/12 Form 10-Q Dare Bioscience, Inc. For: Sep 30 -13.6%

5/8 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research -12.9%

12/18 Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study -12.7%

9/11 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock. -12.2%

1/23 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%

4/1 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® -10.5%

9/11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics -10.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}